# Solid Organ Transplant Infections

## Timeline of Infections Post-Transplant

### The Fishman Framework

The approach to infections in solid organ transplant recipients is anchored by the Fishman timeline, which divides the post-transplant period into three distinct phases, each characterized by a predictable spectrum of infectious pathogens. Understanding this framework is essential to formulating an appropriate differential diagnosis when a transplant recipient presents with fever or other signs of infection.

| Post-Transplant Phase | Timeline | Bacterial | Viral | Fungal | Other |
|---|---|---|---|---|---|
| Early | 0-1 month | Wound infections, HAP, UTI, CLABSI, C. difficile | HSV reactivation | Candida (surgical site, candidemia) | Donor-derived infections |
| Intermediate | 1-6 months | Listeria, Nocardia | CMV (peak months 1-4), BK virus, EBV/PTLD | Aspergillus, PCP, endemic mycoses | Toxoplasma (heart Tx), TB reactivation |
| Late | >6 months | Community-acquired infections (if minimal IS) | Late CMV, PTLD, JC virus/PML | Endemic mycoses (if augmented IS) | Recurrent hepatitis (liver Tx) |

The early post-operative period, spanning month zero through one, is dominated by nosocomial and surgical site infections, donor-derived infections, and reactivation of latent infections present in the recipient before transplantation. Bacterial infections during this phase include wound infections, healthcare-associated pneumonia, urinary tract infections, central line-associated bloodstream infections, and Clostridioides difficile colitis. Herpes simplex virus reactivation is the most common viral event in the immediate post-operative period, and Candida species may cause surgical site infections or candidemia, particularly in the setting of abdominal transplant procedures.

The intermediate period, spanning months one through six, corresponds to the period of peak immunosuppression and is dominated by opportunistic infections. Cytomegalovirus disease peaks during months one through four and represents the single most important viral infection in this phase. BK virus emerges as a significant threat in kidney transplant recipients, and Epstein-Barr virus may drive the development of post-transplant lymphoproliferative disorder. Fungal pathogens including Aspergillus, Pneumocystis jirovecii, and endemic mycoses become relevant. Other opportunistic organisms encountered during this phase include Toxoplasma gondii (particularly in heart transplant recipients), Nocardia, Listeria monocytogenes, and Mycobacterium tuberculosis reactivation.

The late period, beyond six months, is characterized by a bifurcation of risk. Patients on minimal maintenance immunosuppression who have not experienced rejection episodes generally face an infection risk profile similar to the general population, with community-acquired respiratory infections, urinary tract infections, and typical seasonal illnesses predominating. In contrast, patients who have required augmented immunosuppression for chronic rejection episodes or allograft dysfunction remain at elevated risk for opportunistic infections. Late complications in this latter group include late-onset CMV disease, PTLD driven by EBV, JC virus-associated progressive multifocal leukoencephalopathy, and recurrence of hepatitis in liver transplant recipients.

### Net State of Immunosuppression

The concept of the net state of immunosuppression provides a framework for understanding why individual transplant recipients vary in their susceptibility to infection. This cumulative immunosuppressive burden is determined by multiple factors, including the intensity, duration, and type of the immunosuppressive regimen; the dose and duration of corticosteroid therapy; the history and frequency of rejection episodes requiring augmented immunosuppression; the presence of coexisting viral infections such as CMV and hepatitis C, which themselves exert immunomodulatory effects; and metabolic conditions including diabetes, uremia, and malnutrition. A higher net immunosuppressive burden translates directly into a greater risk of infection, and this individualized assessment should guide the aggressiveness of diagnostic evaluation and empiric therapy in any transplant recipient presenting with infectious symptoms.

<image>A timeline infographic showing the three phases of infection risk after solid organ transplantation. Create a horizontal timeline from "Month 0" to "Month 12+" divided into three colored zones: "Early (0-1 month)" in red, "Intermediate (1-6 months)" in orange, and "Late (>6 months)" in green. Within each zone, list the major pathogens organized by category (bacterial, viral, fungal, other). Show key events along the timeline: "Surgery," "Peak immunosuppression," "Taper to maintenance," "Stable immunosuppression." Include a parallel bar showing "Prophylaxis regimens" with timing: TMP-SMX (6-12 months), valganciclovir (3-6 months), and antifungal (organ-specific). Below, show a curve labeled "Risk of OIs" that peaks at months 1-4 and gradually declines. Use the Fishman framework style with clean medical education aesthetics.</image>

## Pre-Transplant Screening

### Donor and Recipient Evaluation

Pre-transplant screening for infectious diseases in both the donor and recipient is a critical step that informs risk stratification, prophylactic strategies, and post-transplant monitoring protocols. This evaluation must be comprehensive and standardized.

Cytomegalovirus serostatus of both donor and recipient is among the most important variables assessed before transplantation. The highest-risk combination is a CMV-seropositive donor with a CMV-seronegative recipient (D+/R-), which places the recipient at risk for primary CMV disease. Intermediate risk is conferred by D+/R+ or D-/R+ combinations, representing reactivation risk, while the D-/R- combination carries the lowest risk. Epstein-Barr virus serostatus follows a similar paradigm, with the D+/R- combination carrying the highest risk for PTLD, particularly in pediatric recipients. Toxoplasma IgG testing is critical in heart transplant recipients because of the risk of reactivation of donor-derived Toxoplasma in a seronegative recipient, as the cysts residing in the donor myocardium can reactivate under immunosuppression.

Screening for latent tuberculosis infection using an interferon-gamma release assay or tuberculin skin test is recommended for all candidates. Treatment of latent tuberculosis should ideally be completed before transplantation because rifampin, the cornerstone of LTBI therapy, has profound drug interactions with calcineurin inhibitors that make post-transplant use extraordinarily difficult. Isoniazid or rifampin can be used pre-transplant; isoniazid is the more practical option if treatment must be given post-transplant.

Hepatitis B and C serologies, including HBsAg, anti-HBc, anti-HBs, HCV antibody, and HCV nucleic acid testing, are mandatory. HIV testing, RPR or VDRL for syphilis, Strongyloides serology for patients from endemic areas, Trypanosoma cruzi serology for patients with epidemiologic links to Latin America, and Coccidioides serology for patients from endemic regions should all be performed. Donor-derived infection screening includes testing for HIV, HBV, HCV, HTLV, CMV, EBV, and syphilis, with nucleic acid testing for HIV, HBV, and HCV performed to minimize the risk of window period transmission. Strongyloides screening of donors from endemic areas is also recommended.

## CMV in Transplantation

### Epidemiology and Risk

Cytomegalovirus is the single most important viral pathogen in solid organ transplantation and remains a major source of morbidity despite advances in prophylaxis and treatment. The D+/R- serostatus combination carries the highest risk, with approximately 50 to 80 percent of patients developing CMV disease in the absence of prophylaxis, reflecting primary infection in an immunologically naive host. Seropositive recipients (R+) face a reactivation risk of approximately 20 to 40 percent without prophylaxis. Risk is further amplified by the use of T-cell-depleting agents, particularly anti-thymocyte globulin, as well as high-dose corticosteroids administered for rejection episodes and other lymphocyte-depleting induction agents.

### Clinical Syndromes

CMV disease in transplant recipients manifests across a spectrum that ranges from a systemic viral syndrome to tissue-invasive disease. CMV syndrome is characterized by fever, malaise, and cytopenias, most notably leukopenia and thrombocytopenia, often accompanied by elevated liver function tests. Tissue-invasive disease involves end-organ involvement, with colitis being the most common gastrointestinal manifestation, followed by hepatitis and pneumonitis. CMV pneumonitis carries the highest mortality in lung transplant recipients. Less common manifestations include retinitis and encephalitis or ventriculitis.

Beyond its direct clinical effects, CMV exerts important indirect effects that are increasingly recognized as central to its overall impact on transplant outcomes. As an immunomodulatory virus, CMV increases the risk of other opportunistic infections through further suppression of the already compromised immune system. Additional indirect effects include an increased risk of allograft rejection, allograft vasculopathy in heart transplant recipients, bronchiolitis obliterans in lung transplant recipients, and graft loss in kidney transplant recipients.

### Prevention Strategies

Two validated strategies exist for the prevention of CMV disease in transplant recipients: universal prophylaxis and pre-emptive monitoring. Universal prophylaxis involves administering valganciclovir 900 milligrams orally once daily, with dose adjustment for renal function, for a defined period post-transplant. For D+/R- patients, who are at highest risk, prophylaxis is typically continued for six months, with some lung transplant programs extending prophylaxis to twelve months. For R+ patients, three months of prophylaxis is standard for kidney transplant recipients and six months for other organs. The advantage of universal prophylaxis is the prevention of both CMV disease and its indirect effects. Disadvantages include bone marrow suppression (particularly neutropenia), cost, and the phenomenon of late-onset CMV, which may occur after prophylaxis is discontinued.

The pre-emptive monitoring approach involves weekly measurement of CMV quantitative PCR viral loads and initiation of antiviral therapy only when viremia exceeds a defined threshold, which varies by center but is typically greater than 1,000 international units per milliliter. This approach has the advantage of avoiding medication toxicity and allowing the development of natural CMV-specific immune responses. Its disadvantage is the requirement for reliable monitoring infrastructure and patient compliance with frequent blood draws. Both strategies are endorsed as acceptable by the 2019 IDSA solid organ transplant guidelines.

### Treatment

Treatment of CMV disease is stratified by severity. For mild disease, valganciclovir 900 milligrams orally twice daily for three to six weeks with weekly quantitative PCR monitoring is appropriate. For severe or tissue-invasive disease, treatment should be initiated with intravenous ganciclovir at 5 milligrams per kilogram every twelve hours until clinical improvement and declining viremia, followed by step-down to oral valganciclovir 900 milligrams twice daily. The minimum treatment duration is three weeks, and therapy should continue until two consecutive negative or low-level CMV PCR results have been documented, with some centers requiring one to two negative PCR results obtained one week apart before stopping therapy.

Ganciclovir-resistant CMV should be suspected when viremia continues to rise or fails to decline after two or more weeks of appropriate therapy at adequate doses. The most common resistance mechanism is a mutation in the UL97 kinase gene, which confers resistance to ganciclovir but not to foscarnet, the standard second-line agent administered at 90 milligrams per kilogram intravenously every twelve hours. Mutations in the UL54 DNA polymerase gene may confer broader multi-drug resistance. Maribavir, a UL97 kinase inhibitor approved by the FDA in 2021 for the treatment of refractory or resistant CMV post-transplant, represents a significant therapeutic advance. Administered at 400 milligrams orally twice daily, maribavir demonstrated superiority over investigator-assigned therapy in the SOLSTICE trial for refractory and resistant CMV. Letermovir, approved for CMV prophylaxis in HSCT recipients, is being investigated for use in solid organ transplant with increasing off-label utilization. Reduction of immunosuppression is an essential adjunctive measure in all cases of CMV disease, and consideration should be given to switching from mycophenolate to a lower-risk immunosuppressive agent.

## EBV and Post-Transplant Lymphoproliferative Disorder (PTLD)

### Risk and Pathogenesis

Post-transplant lymphoproliferative disorder represents the uncontrolled proliferation of B cells driven by Epstein-Barr virus in the setting of profound T-cell immunosuppression. The loss of EBV-specific cytotoxic T-cell surveillance allows EBV-infected B cells to proliferate unchecked. The highest risk is in D+/R- recipients who experience primary EBV infection after transplantation, and children are at higher risk than adults because they are more likely to be EBV-seronegative at the time of transplant. PTLD encompasses a histologic spectrum that ranges from early lesions, including reactive plasmacytic hyperplasia, through polymorphic PTLD, to monomorphic PTLD, which typically presents as diffuse large B-cell lymphoma, and finally to classic Hodgkin-like PTLD.

### Monitoring and Prevention

Monitoring for PTLD involves serial quantitative EBV PCR surveillance in high-risk D+/R- patients. A rising EBV viral load should prompt consideration of reduction of immunosuppression as a preemptive measure. Notably, there is no proven antiviral prophylaxis effective against EBV-driven PTLD, in contrast to the availability of prophylactic strategies for CMV.

### Treatment

The treatment of PTLD is staged and depends on the histologic subtype and severity. Reduction of immunosuppression is the first and most important therapeutic intervention and achieves a response in 20 to 50 percent of early lesions. Rituximab, an anti-CD20 monoclonal antibody, is used for CD20-positive PTLD and achieves response rates of 40 to 60 percent. For aggressive, rituximab-refractory, or monomorphic PTLD, chemotherapy with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is employed. Adoptive immunotherapy with EBV-specific cytotoxic T lymphocytes represents an emerging therapeutic approach with growing evidence of efficacy.

## BK Virus in Kidney Transplant

### Clinical Significance

BK virus-associated nephropathy is the leading cause of allograft dysfunction and loss in kidney transplant recipients, affecting approximately 5 to 10 percent of all kidney transplants. The clinical spectrum progresses from asymptomatic viruria, to detectable viremia, to histologically confirmed nephropathy, and ultimately to graft loss if the process is not recognized and addressed.

### Monitoring

Monitoring for BK virus involves regular measurement of quantitative BK virus PCR in the blood. Current guidelines recommend screening monthly for the first six months post-transplant, then every three months through year two. A viremia level exceeding 10,000 copies per milliliter is considered presumptive evidence of BK virus-associated nephropathy, and kidney biopsy should be considered for histologic confirmation. On histopathology, characteristic findings include viral cytopathic changes with ground-glass intranuclear inclusions, tubulitis, and interstitial nephritis. Immunohistochemical staining for SV40 large T-antigen confirms polyomavirus infection in tissue.

### Management

The primary and most important intervention for BK virus-associated nephropathy is reduction of immunosuppression. The typical approach is to first reduce mycophenolate, either by decreasing the dose by 50 percent or by switching to an mTOR inhibitor such as sirolimus or everolimus, and if viremia persists, to subsequently reduce the calcineurin inhibitor dose. There is no proven antiviral therapy for BK virus, and agents such as cidofovir and leflunomide lack robust evidence of efficacy. Intravenous immunoglobulin has been used anecdotally, but its benefit remains unestablished.

<image>A comparison table of the major viral infections in solid organ transplant recipients. Create a four-column grid for CMV, EBV/PTLD, BK Virus, and HSV/VZV. Rows should include: "Peak timing post-transplant," "Highest-risk serostatus," "Clinical manifestations," "Diagnostic method," "Prevention strategy," "First-line treatment," and "Key monitoring parameters." Include specific details: CMV (D+/R-, month 1-6, quantitative PCR, valganciclovir prophylaxis vs. pre-emptive), EBV (D+/R-, any time, quantitative PCR, reduction of immunosuppression + rituximab), BK (any, month 1-12, quantitative PCR in blood, reduction of immunosuppression), HSV/VZV (any, early, clinical + PCR, acyclovir/valacyclovir prophylaxis). Use color coding by virus family and include small viral icons. Professional medical education table format.</image>

## Other Important Transplant Infections

### Pneumocystis jirovecii

Prophylaxis against Pneumocystis jirovecii pneumonia is standard in all solid organ transplant recipients and consists of trimethoprim-sulfamethoxazole double-strength administered daily or three times weekly for six to twelve months post-transplant. Some programs extend prophylaxis indefinitely in patients who require augmented immunosuppression. Breakthrough PCP on trimethoprim-sulfamethoxazole prophylaxis is exceedingly rare, and when it occurs, management follows the same principles as in non-transplant immunosuppressed patients.

### Nocardia

Nocardia infection occurs more frequently in lung transplant recipients than in recipients of other organs and typically manifests beyond six months post-transplant. It is strongly associated with high-dose corticosteroid therapy. Pulmonary disease, characteristically presenting as nodular infiltrates, is the most common manifestation. Critically, approximately 30 percent of patients with pulmonary nocardiosis have concomitant central nervous system involvement, often in the form of brain abscesses that may be clinically silent, mandating brain imaging in all patients with diagnosed Nocardia infection. Treatment consists of trimethoprim-sulfamethoxazole as the backbone agent, with the addition of imipenem or amikacin for severe disease. Treatment duration is prolonged, typically six to twelve months, and reduction of immunosuppression is an important adjunctive measure.

### Strongyloides Hyperinfection

Strongyloides stercoralis can be acquired either through donor-derived transmission or through reactivation of latent infection in the recipient. Immunosuppression, and particularly corticosteroid therapy, disrupts the host immune mechanisms that normally contain the Strongyloides autoinfective cycle, triggering hyperinfection syndrome. During hyperinfection, the massive burden of migrating larvae carries enteric bacteria through the intestinal wall, leading to gram-negative bacteremia and meningitis with enteric organisms, a clinical scenario that should always raise suspicion for underlying Strongyloides. All donors and recipients from endemic areas should be screened with Strongyloides serology, and positive results should be treated with ivermectin before transplantation. Treatment of hyperinfection requires ivermectin at 200 micrograms per kilogram daily, continued until larvae are undetectable, which requires a minimum of two weeks.

### Donor-Derived Infections

Unexpected donor-derived infections remain a risk despite comprehensive screening protocols. In the current era of nucleic acid testing, window-period transmission of HIV, HCV, and HBV is extremely rare but not eliminated entirely. Endemic infections that may be transmitted from the donor include Strongyloides, Trypanosoma cruzi, West Nile virus, and tuberculosis. Organ procurement organizations maintain notification protocols for the identification and communication of unexpected donor infections to transplant centers, enabling prompt evaluation and treatment of recipients.

## Drug Interactions with Immunosuppressants

### Calcineurin Inhibitors (Tacrolimus, Cyclosporine) and mTOR Inhibitors (Sirolimus, Everolimus)

Drug interactions between antimicrobial agents and immunosuppressive medications represent one of the most clinically consequential aspects of managing infections in transplant recipients. Calcineurin inhibitors and mTOR inhibitors are metabolized by the cytochrome P450 3A4 enzyme and are substrates for P-glycoprotein, rendering them susceptible to significant pharmacokinetic interactions.

Azole antifungals increase calcineurin inhibitor and mTOR inhibitor levels through potent CYP3A4 inhibition. Voriconazole and posaconazole are the most potent inhibitors, and co-administration requires a 50 to 75 percent reduction in the calcineurin inhibitor dose with frequent therapeutic drug monitoring. Itraconazole has similar effects, while fluconazole produces dose-dependent inhibition that is less pronounced at lower doses but still clinically significant. Failure to anticipate and manage these interactions can result in calcineurin inhibitor toxicity, including nephrotoxicity and neurotoxicity.

Rifamycins dramatically decrease calcineurin inhibitor and mTOR inhibitor levels through potent CYP3A4 induction. Rifampin is effectively contraindicated in transplant recipients, as it reduces calcineurin inhibitor levels by approximately 90 percent, precipitating acute rejection. Rifabutin is a less potent inducer but should be used only with extreme caution, close therapeutic drug monitoring, and significant dose adjustment of the immunosuppressive agent.

## Key Clinical Pearls

- The Fishman timeline (early, intermediate, late) is the framework for approaching infection in transplant recipients -- the timing tells you the likely pathogen
- CMV D+/R- mismatch carries the highest risk for CMV disease -- these patients require 6 months of prophylaxis
- Maribavir is the first FDA-approved drug for ganciclovir-resistant/refractory CMV in transplant recipients -- a game-changer for this difficult clinical problem
- Reduction of immunosuppression is both the first and most important therapeutic intervention for PTLD, BK nephropathy, and many viral infections
- TMP-SMX prophylaxis for PCP should be continued for 6-12 months in all SOT recipients -- it also provides Nocardia and Toxoplasma coverage
- Always image the brain in Nocardia infection -- 30% have CNS involvement that may be asymptomatic
- Screen for Strongyloides in all donors/recipients from endemic areas BEFORE transplant -- hyperinfection syndrome post-transplant has >50% mortality
- Drug interactions between azole antifungals and calcineurin inhibitors are universal and dangerous -- reduce dose and monitor levels closely

## References
1. Fishman JA. Infection in organ transplantation. *N Engl J Med*. 2007;357(25):2601-2614.
2. Kotton CN, Kumar D, Caliendo AM, et al. The Third International Consensus Guidelines on the management of CMV in solid-organ transplantation. *Transplantation*. 2018;102(6):900-931.
3. Avery RK, Arav-Boger R, Marr KA, et al. Outcomes in transplant recipients treated with maribavir for resistant or refractory CMV (SOLSTICE). *N Engl J Med*. 2022;386(10):951-963.
4. Allen UD, Preiksaitis JK; AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation. *Am J Transplant*. 2019;19(Suppl 2):28-46.
5. Hirsch HH, Randhawa PS; AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation. *Am J Transplant*. 2019;19(Suppl 3):71-88.